Appendix cancer other imaging findings
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Positron emission tomography (PET) and scintigraphy are among other imaging modalities that may be helpful in the diagnosis and management of appendix cancer.
Other Imaging Findings
- The followings are among other imaging modalities that may be helpful in the diagnosis and management of appendix cancer:
- Somatostatin scintigraphy with 111-indium-octreotide[1]
- High sensitivity and specificity for both functioning and non-functioning carcinoid tumors
- Most sensitive imaging method to evaluate extrahepatic metastases
- Useful in treatment planning
- Indicates response to octreotide analogues
- Bone scintigraphy with 99mTc-methylene diphosphonate (99mTcMDP)[2]
- MIBG scintigraphy [2]
- Distinguish between primary and metastatic tumors
- Detecting carcinoid tumors that are negative on OctreoScan
- Positron emission tomography (PET):
- PET–CT scan will show high uptake in the metastasis points as well residual tumor and/or peritoneal carcinomatosis.
- Figure below demonstrates post-operative PET-CT scan of a patient with carcinoid tumor.[3]
References
- ↑ Kisker O, Bartsch D, Weinel RJ, Joseph K, Welcke UH, Zaraca F et al. (1997) The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg 184 (5):487-92. PMID: 9145069
- ↑ 2.0 2.1 Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. (2001) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86 (2):895-902. DOI:10.1210/jcem.86.2.7194 PMID: 11158063
- ↑ Sundin A, Eriksson B, Bergström M, Långström B, Oberg K, Orlefors H (2004) PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 1014 ():246-57. PMID: 15153441
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH